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The nature of thyroid hormone uptake into the cell and the possible involvement of the serum carrier pro- 
teins and receptor-mediated endocytosis n this process are reviewed. The evidence that there is a specific 
thyroid hormone-binding receptor in the inner mitochondrial membrane and the relation of this to the aden- 
ine nucleotide translocator is discussed. Direct effects of thyroid hormone on mitochondrial function that 
might be mediated by such a receptor are also considered. 
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1. INTRODUCTION 
The transport of the thyroid hormones 
3,5,3'-tri iodo-L-thyronine and L-thyroxine in the 
blood bound to albumin and thyroid binding 
globulin (human) or serum prealbumin (rat) is well 
known. Recently it has become clear that the up- 
take of thyroid hormone into cells is carrier 
mediated and that cells are able to maintain a free 
T3 concentration greater than plasma. This has im- 
portant implications for the control of whole body 
metabolism. It has been assumed that basal 
metabolism is largely controlled via a classical 
feedback inhibition between the thyroid and the 
hypothalamus/pituitary to control the free T3 con- 
centration, that in turn determined the basal 
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metabolic rate of the organism. If  the cell can con- 
trol its own level of T3 this view becomes too 
simplistic to be of much value. The mitochondria 
have also been suggested to be a site of direct T3 ac- 
tion. The ability of the cell to regulate its own free 
T3 concentration could provide a means for the cell 
to control the efficiency of mitochondrial respira- 
tion. It is therefore important o characterise the 
mechanism of T3 uptake into the cell and the possi- 
ble direct effects of this process on mitochondrial 
function, as this will place constraints on future 
models of the control of basal metabolism. 
2. UPTAKE OF THYROID HORMONE INTO 
THE CELL 
The inability of T3 to cross the plasma mem- 
brane because of the functional pore size of the 
membrane as well as the charged nature of T3 at 
physiological pH led Rao et al. [1] to investigate 
the translocation of thyroid hormone into isolated 
rat liver cells. They presented the first evidence 
that this process was carrier mediated and that the 
free T3 concentration i the cell is greater than that 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/87/$3.50 © 1987 Federation of European Biochemical Societies 251 
Volume 224, number 2 FEBS LETTERS November 1987 
in the plasma [1]. Since then evidence has also been 
presented for a carrier-mediated uptake of thyroid 
hormone into isolated rat adipocytes [2], cultured 
mouse fibroblasts [3] and human red cell ghosts 
[4]. The finding that 30 out of 32 tissues in the rat 
exhibit a tissue-to-plasma gradient of T3 [5] sug- 
gests that an even larger number of tissues may 
have active T3 uptake, although the possibility that 
the tissue-to-plasma gradients in at least some of 
these sites are a consequence of intracellular 
binding cannot be excluded. 
The uptake system in the rat hepatocyte is 
probably the best characterised. There appear to 
be two uptake systems, one high-affinity/low- 
capacity, and one low-affinity/high-capacity [1] 
for both T3 and T4 [6]. The low-affinity system has 
been suggested to represent binding to the cell sur- 
face as it can be eliminated by washing the cells 
with a medium containing thyroid binding globulin 
[6]. Analysis of the mutual inhibition of Ta and T4 
uptake indicated that the high-affinity transport 
systems involved for T3 and T4 uptake are not the 
same [6]. These carriers exhibit saturable uptake 
[1,6] with defined Vmax and Km values. The process 
is energy dependent, and can be inhibited by 
oligomycin, cyanide and ouabain [6,7]. The oua- 
bain sensitivity indicates that an Na ÷ gradient may 
be important in the uptake of T3. Further 
characterisation has indicated that the uptake is 
likely to be mediated by a glycoprotein. This is 
based on the sensitivity of the uptake to ~- 
glucosidase, pronase and neuraminidase [7] as well 
as the inhibition of T3 uptake by a monoclonal an- 
tibody that did not inhibit the Na ÷,K÷-ATPase [8]. 
The uptake into cells has also been shown to be 
sensitive to 6-n-propyl-2-thiouracil and the 
microtubule-disrupting agents vinblastine and col- 
chicine [9]. 
2.1. The role of  serum carrier proteins 
Some workers have been unable to identify ac- 
tive T3 transport across the plasma membrane in 
isolated hepatocytes [10] while they did observe 
evidence for a free T3 concentration difference be- 
tween plasma and cytosol of kidney, liver and 
brain in situ [11]. This suggests the possibility of 
some direct involvement of a plasma component in 
facilitating active transport into the cell. Serum 
albumin appears to increase the [/max of the high- 
and low-affinity uptake systems in isolated 
hepatocytes without altering the Km of either pro- 
cess [12]. This has been proposed to be due to 
enhanced iffusion through the unstirred layer at 
the cell surface [12]. A passive role for albumin in 
establishing a cytosol-to-plasma free T3 gradient in 
vivo has been proposed [13] as a result of the in- 
ability of the workers in [10] to observe active 
transport into isolated hepatocytes while they did 
observe a tissue-to-plasma gradient in situ [11]. 
The model suggests that in the (human) hepatic 
microcirculation, dissociation of T3 from albumin 
and thyroid binding globulin is enhanced so that 
the large pools of T3 bound to albumin and thyroid 
binding globulin are available for passive transport 
into the cell. The free T3 cytosol-to-plasma bulk 
phase concentration gradient is proposed to be a 
consequence of a high local free T3 concentration 
in the plasma in the hepatic microcirculation. 
Presumably this model could also be applied to the 
reported free T3 tissue-to-plasma concentration 
gradients reported in situ for kidney and brain 
[11]. However, the evidence for active T3 transport 
into cells presented by several groups for several 
tissues [1-9,14] is sufficiently convincing that 
there is no need to invoke such enhanced iffu- 
sional models. 
Is there any evidence for a more direct role of 
albumin in the transport of T3 into the cell? As far 
as I am aware there has been no evidence presented 
that suggests albumin may enter the cell. There 
have, however, been reports that serum 
prealbumin (in the rat) or thyroid binding globulin 
(in man) may be transported into the cell. Evidence 
has been presented that prealbumin is able to pass 
through the plasma membrane into the cell [15]. 
This evidence was based upon monospecific an- 
tiserum assays and electron-microscopic 
radioautography of liver, brain and spleen after 
the injection of 125I-labelled prealbumin or T3. 
These authors have suggested that prealbumin 
complexed to T3 can directly penetrate the plasma 
membrane. In another study [16] it was 
demonstrated that the Ta-binding protein in 
human breast adipose tissue is similar to serum 
thyroid binding globulin with respect o thermal 
inactivation profiles of binding and sensitivity to 
thiol group blocking agents. The cytosolic 
T3-binding protein was also found to cross-react 
with a monospecific antiserum to human thyroid 
binding globulin. This evidence indicates that 
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thyroid binding globulin (which is synthesised only 
in liver) may be present in adipose tissue cytosol. 
Further experiments are required to clarify this 
situation. 
If the uptake of thyroid hormone into the cell ,is 
mediated by thyroid binding globulin (or 
prealbumin in the rat), what is the role of the 
T3-binding proteins present on the cell membrane 
[14]? It is possible that the T3-binding proteins at 
the cell surface have no functional role in the up- 
take of T3 into the cell. For example, it has been 
shown that in the red blood cell the activity of the 
plasma membrane Ca2÷-ATPase is controlled 
directly by T3 [17,18]. This has also been shown to 
be true in the myocardium [19]. This enzyme 
would appear as a T3-binding protein in T3-binding 
assays, but it is not expected to be involved in the 
transport of T3 into the cell. Recently the sequence 
of the membrane-associated thyroid hormone- 
binding protein from bovine liver has been deter- 
mined [20]. This protein was shown to be 93o70 
homologous with rat protein disulphide isomerase. 
Is this a functional relationship? In the absence of 
assays for uptake the presence of T3-binding pro- 
teins on the plasma membrane does not exclude 
simultaneous serum carrier protein uptake. 
2.2. The possibility of receptor-mediated 
endocytosis 
If the carrier proteins are taken up into the cell 
as suggested by the work cited above, could 
receptor-mediated endocytosis be involved? 
Receptor-mediated endocytosis has been indicated 
in a previous study [21], where a rhodamine 
derivative of T3 bound to specific binding sites on 
the cell surface, that clustered over clathrin coated 
pits prior to endocytosis. If T3 entered the cell by 
receptor-mediated endocytosis it could do so 
bound to its transport system in a manner 
analogous to the transferrin iron-uptake system. 
This might explain the apparent localisation of 
thyroid binding globulin within (human) breast 
adipose tissue [16] and serum prealbumin in rat 
hepatocytes [15]. A receptor-mediated endocytosis 
of Ta would also be consistent with the sensitivity 
of T3 uptake into cells to the microtubule- 
disrupting agents vinblastine and colchicine [9]. If 
receptor-mediated endocytosis involved then the 
suggestion that the membrane protein that binds 
T3 is protein disulphide isomerase [20] acquires 
greater significance. This protein is characteristi- 
cally associated with protein folding. If as has been 
suggested thyroid binding globulin [16] and preal- 
bumin [15] are able to enter the cytosol, the 
involvement of this protein might provide a 
mechanism that allowed entry of the carrier 
protein into the cell, in a manner analogous to the 
reverse of secretory protein transport into the en- 
doplasmic reticulum during protein synthesis. 
However, a receptor-mediated vent cannot ex- 
plain the uptake of T3 into plasma membrane 
vesicles; which is not sensitive to microtubule- 
disrupting agents [9]. 
3. LOCALISATION OF THYROID HORMONE 
TO THE MITOCHONDRIA 
The mitochondria have received much attention 
as possible sites of thyroid hormone action, 
although a convincing demonstration of a direct 
effect of T3 on mitochondrial function is lacking. 
There are many reports in the literature of T3 
rapidly associating with the mitochondria after ad- 
ministration to hypothyroid or euthyroid rats. 
However, a major discrepancy exists as to whether 
this association is specific or nonspecific. 
Using electron-microscopic radioautography 
following administration of ~zSI-T3 to isolated 
hepatocytes [22] the mitochondria were identified 
as the only obvious site of T3 accumulation during 
the first 30 min after administration. In another 
study injection of labelled T3 into thyroidecto- 
mised rats led to a rapid localisation of T3 to the 
mitochondria that then decreased over the next 3 h 
[23]. The interpretation of this study is made more 
difficult by apparent changes in the so-called 
'cytosolic free protein concentration' during the 
first hour after T3 administration. The finding that 
there was no change in the nuclear T3 content dur- 
ing the first 4 h after T3 administration in this 
study is also contrary to currently accepted 
schemes [10]. 
3.1. A thyroid hormone receptor in the inner 
mitochondrial membrane? 
The question as to whether the distribution of 
thyroid hormone to the mitochondria is specific or 
nonspecific has been investigated by several 
groups. Sterling and co-workers [24,25] have 
reported a specific T3-binding activity in the inner 
253 
Volume 224, number 2 FEBS LETTERS November 1987 
mitochondrial membrane, but no binding to the 
outer mitochondrial membrane. This binding ac- 
tivity was identified in mitochondria from liver, 
kidney, myocardium and skeletal muscle, but not 
in brain, spleen and testis which do not respond to 
thyroid hormone with increased heat production. 
The association constants of thyroid hormone 
analogues to this inner mitochondrial binding ac- 
tivity correlated well with their physiological 
potency. In another study using gel filtration four 
T3-binding activities in the outer mitochondrial 
membrane and two major T3-binding activities in 
the inner mitochondrial membrane have been iden- 
tified [26]. However, other studies have been inter- 
preted in favour of nonspecific association of 
thyroid hormone with the mitochondria. For ex- 
ample, in the initial characterisation f the nuclear 
thyroid hormone receptor [27] under conditions 
specifically devised to identify thyroid hormone 
receptors, a rapid binding of 125I-T3 to mitochon- 
dria at 37°C was observed. Because the mitochon- 
drial binding showed similar kinetics at 0°C to 
those at 37°C while the nuclear binding was com- 
pletely inhibited at 0°C, it was concluded that the 
mitochondrial binding was nonspecific. In another 
study following the localisation of a small dose of 
labelled T3 2 min after injection into thyroidec- 
tomised rats [28] it was concluded, on the basis of 
the inability to excess cold T3 to displace the la- 
belled T3, that no specific binding site existed for 
T3 in the mitochondria. The reason for these ap- 
parent discrepancies i  not known. In the absence 
of a good functional assay (see below) for these 
putative receptors it is difficult to conclude that 
they have a physiological action. 
3.2. The adenine nucleotide translocator as a 
thyroid hormone receptor 
Subsequent to the initial reports from Sterling's 
laboratory of a T3-binding protein in the inner 
mitochondrial membrane [24,25], Sterling [29] has 
suggested that the adenine nucleotide translocator 
may be the T3 receptor. This suggestion was based 
on the co-purification of label with the adenine 
nucleotide translocator after photoaffinity la- 
belling with 125I-T3. The lack of demonstration i  
this stsudy that mitochondrial proteins in general 
were not labelled makes the result less certain. The 
long incubation times used (24 h) make it possible 
that this binding was merely a consequence of at- 
tachment of the label to all mitochondrial proteins. 
In the earlier eports from Sterling's laboratory the 
T3-binding activity was partially purified as a pro- 
teolipid with a molecular mass of 150 kDa [25]. 
The molecular mass of the adenine nucleotide 
translocator (31 kDa) makes it difficult to suggest 
that this is the same fraction as earlier identified. 
If the adenine nucleotide translocator is the 
mitochondrial T3 receptor in liver, then the 
absence of the mitochondrial inner membrane T3 
receptor in brain, spleen and testis previously 
reported by Sterling's group [24,25] makes it 
necessary to postulate a different adenine 
nucleotide translocator in these tissues. 
3.3. Transport of  thyroid hormone to the 
mitochondria 
The nature of the transport of T3 to the 
mitochondria has not received much attention. It 
has been reported that the cytosolic T3-binding 
protein increases the uptake of T3 into isolated 
kidney mitochondria [30]. In an extension of the 
studies which indicated that T~ was taken up into 
the cell in association with serum prealbumin in the 
rat [15] the same workers have indicated that 
serum prealbumin is targetted to the inner 
mitochondrial membrane [31 ], and have 
postulated that it binds to an 'acceptor' protein 
there to exert its effects. This involvement of a 
serum carrier protein in the subcellular distribution 
of thyroid hormone is not consistent with current 
views of intracellular transport and deserves fur- 
ther investigation. 
3.4. Direct effects of thyroid hormone on 
mitochondrial function 
The major problem in determining whether 
these putative T3 receptors in the inner mitochon- 
drial membrane are physiologically relevant or not 
is the lack of adequate xperimental demonstration 
of any direct effect of T3 on mitochondria. The 
main evidence that has been used by Sterling's 
group for a direct action of T3 on mitochondria is
a stimulation of the respiration rate of mitochon- 
dria isolated 30 min after the injection of T3 into 
a rat in the presence of protein synthesis inhibitors 
[32]. The highly variable nature and size of this ef- 
fect make its interpretation difficult. Other groups 
have reported no increase in mitochondrial respira- 
tion rate 15 min after the injection of T3 into 
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thyroidectomised rats [23]. The possibility that the 
adenine nucleotide translocator is the mitochon- 
drial T3 receptor is not consistent with the action 
of T3 on mitochondria being to increase respiration 
rate. The adenine nucleotide translocator has a 
lower flux control coefficient compared to control 
over respiration rate in mitochondria solated from 
hypothyroid rats [33,34]. This makes it unlikely 
that stimulation of this step would increase the 
respiration rate. 
In support of the adenine nucleotide carrier be- 
ing a thyroid hormone responsive lement of the 
inner mitochondrial membrane is the finding that 
the lowered l/max and raised Km of this step, 
characteristic of the hypothyroid state, can be 
restored to normal values within 15 min of the in- 
jection of T3 [35]. Although this supports the idea 
of a rapid effect of T3 on mitochondrial function 
in hypothyroid rats it does not demonstrate hat T3 
acts directly on this step or that it has any action 
at this step in the euthyroid animal. The workers in 
this study used a dose of T3 designed to saturate 
the plasma binding sites and restore the free T3 
concentration to euthyroid levels. The finding that 
the extravascular T3 binding is much larger than 
the intravascular binding [5] indicates that the free 
T3 concentration actually achieved in this study is 
much lower than the euthyroid level. Because the 
kinetics of the carrier were completely restored to 
normal by what would appear to be a free T3 con- 
centration much lower than euthyroid it is hard to 
suggest hat variation of the free T3 concentration 
in the euthyroid animal would be able to regulate 
this step. 
Bronk [36] has shown that the decreased respira- 
tion rate of mitochondria isolated from 
hypothyroid rats can be half restored 3 h after the 
administration of 30/~g of T3. This effect was sug- 
gested to be the result of a direct action of T3 on 
the mitochondria rather than being mediated by 
protein synthesis because the levels of the 
cytochromes did not change over this time course. 
However, the evidence that the cytochromes are 
important in the control of state 3 respiration rate 
in hypothyroid animals is slim (see [37] for a 
review). As the levels of some hepatic messenger 
RNAs have been shown to change within an hour 
of thyroid hormone administration [38] it seems 
premature to conclude that this increase in respira- 
tion was not mediated by protein synthesis. 
A recent report [39] has indicated that Ta added 
in vitro to mitochondria solated from hypothyroid 
rats can control the ADP/O ratio in the presence 
of nanomolar concentrations of free Ca 2÷. 
However, it has been suggested [40] that the ap- 
parent drop in ADP/O ratio previously reported 
by this group [23,34] is a result of net formation of 
phosphate acceptor leading to increased 
phosphorylation of ADP rather than a decreased 
efficiency of ATP synthesis [40]. The apparent 
Ca2+-dependent drop in ADP/O ratio and its 
reversal by T3 [39] may be a consequence of 
Ca2÷-dependent ATPase activity (or an enzymatic 
breakdown of ADP to AMP) that can be inhibited 
by T3 in vitro. It cannot, therefore, be used as 
evidence for a receptor-mediated action of T3 on 
the mitochondria. 
4. CONCLUSIONS 
In conclusion there is apparently sufficient 
evidence that the uptake of thyroid hormones into 
cells is an active mechanism and not passive diffu- 
sion. However, the exact nature of the transloca- 
tion process remains obscure. Both receptor- 
mediated endocytosis and serum carrier proteins 
may be involved, and further experiments are re- 
quired to characterise their roles in the uptake pro- 
cess. As far as the localisation of thyroid hormone 
to the mitochondria is concerned there is insuffi- 
cient evidence for a receptor in the inner mitochon- 
drial membrane or fo r  a direct action of T3 on the 
mitochondria. This localisation may not be a 
specific binding event, but rather a nonspecific 
distribution to a preferred lipid environment. 
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